Date published: 2025-12-7

1-800-457-3801

SCBT Portrait Logo
Seach Input

Lunatic Fringe Inhibitors

Lunatic Fringe inhibitors encompass a specialized class of chemical compounds developed to target and inhibit the activity of Lunatic Fringe, a glycosyltransferase enzyme that plays a crucial role in the Notch signaling pathway. Notch signaling is a fundamental communication system in multicellular organisms that regulates cell differentiation, proliferation, and apoptosis. Lunatic Fringe specifically modifies Notch receptors through the addition of specific sugar molecules, a process known as glycosylation. This modification is critical in regulating the sensitivity of cells to Notch ligands, thereby influencing the outcome of the Notch signaling pathway. The structure of Lunatic Fringe is characterized by specific domains responsible for its enzyme activity, which includes the transfer of N-acetylglucosamine to specific sites on Notch receptors. The activity of Lunatic Fringe is essential for the precise modulation of Notch signaling, making it a target of interest for the development of specific inhibitors.

The creation of Lunatic Fringe inhibitors is a complex process that requires a detailed understanding of the enzyme's structure and its interaction with Notch receptors. The development of these inhibitors focuses on disrupting the glycosyltransferase activity of Lunatic Fringe, thereby modulating the Notch signaling pathway. This process involves the identification of key active sites and functional domains within the Lunatic Fringe enzyme that are critical for its glycosyltransferase activity. Techniques such as X-ray crystallography and NMR spectroscopy are instrumental in determining the three-dimensional structure of Lunatic Fringe, providing insights into inhibitor binding sites. In addition to structural studies, computational methods play a significant role in the design of inhibitors. Molecular modeling and docking simulations are used to predict the interactions between inhibitors and the enzyme, guiding the synthesis of compounds that can effectively bind to and inhibit Lunatic Fringe. The development of these inhibitors is an iterative process, involving the synthesis, testing, and refinement of compounds to achieve optimal inhibition. This research field is continually advancing, driven by the growing understanding of the Notch signaling pathway and its importance in cellular communication and regulation.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Tunicamycin

11089-65-9sc-3506A
sc-3506
5 mg
10 mg
$169.00
$299.00
66
(3)

Tunicamycin, an inhibitor of N-linked glycosylation, could potentially affect Lunatic Fringe expression by disrupting protein glycosylation processes, which are important for its function and stability.

Cyclopamine

4449-51-8sc-200929
sc-200929A
1 mg
5 mg
$92.00
$204.00
19
(1)

Cyclopamine, a Hedgehog signaling pathway inhibitor, might influence Lunatic Fringe expression indirectly by modulating developmental pathways that interact with the Notch signaling pathway.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY294002, a PI3K inhibitor, could affect Lunatic Fringe expression by altering phosphatidylinositol signaling pathways, which are involved in various cellular processes including gene expression.

SB 431542

301836-41-9sc-204265
sc-204265A
sc-204265B
1 mg
10 mg
25 mg
$80.00
$212.00
$408.00
48
(1)

SB431542, an inhibitor of TGF-β signaling, could potentially influence Lunatic Fringe expression by altering signaling pathways that interact with the Notch pathway during development.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin, an mTOR inhibitor, might affect Lunatic Fringe expression by influencing protein synthesis pathways and cellular stress responses, which can regulate gene expression.

Wnt-C59

1243243-89-1sc-475634
sc-475634A
sc-475634B
5 mg
10 mg
50 mg
$210.00
$320.00
$1250.00
1
(0)

Wnt-C59, a Wnt signaling inhibitor, could potentially affect Lunatic Fringe expression by modulating Wnt pathway activity, which often interacts with the Notch pathway in developmental processes.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

PD98059, an inhibitor of MEK, could affect Lunatic Fringe expression by altering the MAPK/ERK pathway, which plays a role in the regulation of gene expression and cellular signaling.

XAV939

284028-89-3sc-296704
sc-296704A
sc-296704B
1 mg
5 mg
50 mg
$35.00
$115.00
$515.00
26
(1)

XAV939, a Wnt/β-catenin pathway inhibitor, might influence Lunatic Fringe expression by modulating Wnt signaling, which can intersect with the Notch pathway in cell fate determination.

IWP-2

686770-61-6sc-252928
sc-252928A
5 mg
25 mg
$94.00
$286.00
27
(1)

IWP-2, an inhibitor of Wnt production, could potentially affect Lunatic Fringe expression by altering Wnt pathway activity and its interaction with the Notch signaling pathway.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125, a JNK inhibitor, might impact Lunatic Fringe expression by modulating JNK signaling pathways, which are involved in cellular stress responses and gene regulation.